BRAF and metastatic melanoma: This compares to an mPFS of 16.8 m (anti-PD-1/CTLA-4), 5.6 m (anti-PD-1), and 3.4 m (anti-CTLA-4) in CHECKMATE-067, and 11.6 m (Anti-PD-1) in KEYNOTE 006, both trials of ICIs in metastatic melanoma, with a pre-specified stratification for patients with BRAF mutations [68,72].